Your browser doesn't support javascript.
loading
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.
Ho, Matthew; Chen, Tianzeng; Liu, Jiye; Dowling, Paul; Hideshima, Teru; Zhang, Li; Morelli, Eugenio; Camci-Unal, Gulden; Wu, Xinchen; Tai, Yu-Tzu; Wen, Kenneth; Samur, Mehmet; Schlossman, Robert L; Mazitschek, Ralph; Kavanagh, Emma L; Lindsay, Sinéad; Harada, Takeshi; McCann, Amanda; Anderson, Kenneth C; O'Gorman, Peter; Bianchi, Giada.
Afiliação
  • Ho M; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Chen T; UCD Conway Institute of Biomolecular and Biomedical Science, UCD School of Medicine, University College Dublin, Belfield (UCD), Dublin 4, Ireland.
  • Liu J; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Dowling P; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Hideshima T; Biology Department, National University of Ireland Maynooth, Co. Kildare, Kildare, Ireland.
  • Zhang L; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Morelli E; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Camci-Unal G; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Wu X; Department of Chemical Engineering, University of Massachusetts Lowell, One University Avenue, Lowell, MA, 01854, USA.
  • Tai YT; Department of Chemical Engineering, University of Massachusetts Lowell, One University Avenue, Lowell, MA, 01854, USA.
  • Wen K; Biomedical Engineering and Biotechnology Program, University of Massachusetts Lowell, One University Avenue, Lowell, MA, 01854, USA.
  • Samur M; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Schlossman RL; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Mazitschek R; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Kavanagh EL; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
  • Lindsay S; Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
  • Harada T; UCD Conway Institute of Biomolecular and Biomedical Science, UCD School of Medicine, University College Dublin, Belfield (UCD), Dublin 4, Ireland.
  • McCann A; UCD Conway Institute of Biomolecular and Biomedical Science, UCD School of Medicine, University College Dublin, Belfield (UCD), Dublin 4, Ireland.
  • Anderson KC; Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.
  • O'Gorman P; UCD Conway Institute of Biomolecular and Biomedical Science, UCD School of Medicine, University College Dublin, Belfield (UCD), Dublin 4, Ireland.
  • Bianchi G; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
Leukemia ; 34(1): 196-209, 2020 01.
Article em En | MEDLINE | ID: mdl-31142847
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Microambiente Tumoral / Células-Tronco Mesenquimais / Histona Desacetilases / Mieloma Múltiplo Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Animals / Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Microambiente Tumoral / Células-Tronco Mesenquimais / Histona Desacetilases / Mieloma Múltiplo Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Animals / Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos